Novartis (NVS) Stock: Buy, Sell, or Hold?
NVS - Novartis AG
$146.88
4.47 (3.14%)
▲
5d:
+2.51%
30d:
+5.96%
90d:
-3.83%
BUY
MODERATE Confidence
Analysis Updated: Oct 14, 2026 12:00 AM ET
Earnings: Oct 27, 2026
11d
Get Alerted When NVS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NVS shows positive signals but monitor for confirmation. Market pricing in 0.9% decline. Moderate conviction.
💡 BUY OPPORTUNITY: NVS shows positive signals but monitor for confirmation. Market pricing in 0.9% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$216.44
Based on 7.5% avg growth
INTRINSIC VALUE TODAY
$134.39
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NVS is currently trading at $146.88, which is considered extended relative to its 30-day fair value range of $138.85 to $144.38. The stock's valuation (Forward PE: 15.0) is in line with its historical norms (15.4). Remarkably, the market is currently pricing in an annual earnings decline of 0.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, NVS is in a uptrend. The price is approaching resistance at $147.16. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: NVS scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NVS is in a uptrend. The price is approaching resistance at $147.16. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: NVS scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$138.85 -
$144.38
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.1%)
- NEUTRAL: Near Wall St target ($154.65)
- BULLISH: Bottoming setup score 60/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$138.85 -
$144.38
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$139.31
Resistance Level
$147.16
Current Trend
Uptrend
Technical data as of
Oct 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.98
Wall Street Target
$154.65
(+5.3%)
Revenue Growth (YoY)
0.8%
Earnings Growth (YoY)
-17.0%
Profit Margin
22.5%
Valuation Discount vs History
-0.9% cheaper
PE vs Historical
15.0 vs 15.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.9%
(market-implied from PE analysis)
1-Year Target
$145.56
(-1%)
2-Year Target
$144.25
(-2%)
3-Year Target
$142.95
(-3%)
3-Yr Target (if PE normalizes)
(PE: 15→15)
$146.92
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 11.0%)
$266.22
(+81%)
Base:
(SPY PE: 15.0, Growth: 11.0%)
$200.86
(+37%)
Bear:
(PE: 12.7, Growth: 11.0%)
$170.73
(+16%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (22x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 21.51 | Current EPS (TTM): $6.62
Bull Case
$231.96
(+58%)
Analyst growth 48.1%, PE expands to 23.7
Base Case
$210.87
(+44%)
Market implied 48.1%, PE stable at 21.5
Bear Case
$96.84
(-34%)
Severe decline -20.0%, PE contracts to 18.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.0 to 15.4
Stabilization Target:
$150.96
(+2.8%)
PE Expansion Potential:
+2.8%
Share & Embed Analysis
Last updated: October 14, 2026 10:50 PM ET
Data refreshes hourly during market hours. Next update: 11:50 PM
Data refreshes hourly during market hours. Next update: 11:50 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
30 analysts |
$1330 | 44 HOLD |
|
GILD
Gilead Sciences Inc |
STRONG BUY
28 analysts |
$159 | 49 HOLD |
|
ABBV
AbbVie Inc |
STRONG BUY
30 analysts |
$281 | 38 SELL |
|
MRK
Merck & Company Inc |
STRONG BUY
27 analysts |
$158 | 55 HOLD |
|
BIIB
Biogen Inc |
BUY
35 analysts |
$239 | 45 HOLD |
